Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114448 | 0.89 | GBA1 (0.34) | GNAI3GNAO1GNAI1TLR9TLR8 | |
| SCHEMBL2116406 | 0.85 | GNAI3 (0.39) | GNAI3GNAO1GNAI1TLR9TLR8 | |
| SCHEMBL2116363 | 0.81 | GNAO1 (0.37) | GNAI3GNAO1GNAI1CYP2D6 | |
| SCHEMBL2118268 | 0.80 | HRH1 (0.37) | GNAI3GNAO1GNAI1TLR9TLR8 | |
| SCHEMBL2115839 | 0.80 | BCHE (0.36) | GBA1 | |
| SCHEMBL14768953 | 0.79 | GNAO1 (0.42) | GNAI3GNAO1GNAI1HRH1 | |
| SCHEMBL15837589 | 0.78 | GBA1 (0.36) | GNAI3GNAO1GNAI1HRH1GBA1 | |
| SCHEMBL2116367 | 0.78 | GBA1 (0.36) | GNAI3GNAO1GNAI1HRH1GBA1 | |
| SCHEMBL2114423 | 0.77 | TLR9 (0.36) | TLR9TLR8TLR7HRH1HTR2A | |
| SCHEMBL2116263 | 0.76 | GNAI3 (0.39) | GNAI3GNAO1GNAI1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | GNAI3 3293/4885GNAO1 2673/4885GNAI1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.